Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myelomaSuzette Girgis, Jenna D. Goldberg, Arnob Banerjee et al.|Blood Advances|2022Cited by 52
Population Pharmacokinetics and Exposure–Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1Xin Miao, Suzette Girgis, Liviawati S. Wu et al.|Targeted Oncology|2023Cited by 46
Teclistamab and talquetamab modulate levels of soluble B-cell maturation antigen in patients with relapsed and/or refractory multiple myeloma.Suzette Girgis, Jenna D. Goldberg, Shun Xin Wang Lin et al.|Journal of Clinical Oncology|2021Cited by 5
Teclistamab Population Pharmacokinetics and Exposure-Response Relationship Support 1.5 Mg/Kg Dose Regimen in Relapsed/Refractory Multiple MyelomaXin Miao, Honghui Zhou, Liviawati S. Wu et al.|Blood|2022Cited by 5
P-001: Modulation of soluble B-cell maturation antigen levels in patients with relapsed and/or refractory multiple myeloma after treatment with teclistamab and talquetamabSuzette Girgis, Jenna D. Goldberg, Shun Xin Wang Lin et al.|Clinical Lymphoma Myeloma & Leukemia|2021Cited by 1